Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365:1333–46.
 Xiaoling C, Yingying L, Xueyao H, et al. A meta-analysis of efficacy and safety of nateglinide in type 2 diabetes mellitus in Asia. Chinese J of Diabet, 2012, 21 (10): 913–917.
 Yong C, Qiuxiang X, Qin L, et al. A comparative study of the clinical efficacy of Naglinide and Acarbose in the treatment of type 2 diabetes mellitus. Modern Chinese Drug Use, 2010, 4:166–167.
 Barroso I, Luan J, Middelberg RP, et al. Candidate gene association study in Type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol. 2003;1: E20.
 Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism predisposes to Type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002; 51: 875–9.
 Barhanin J, Lesage F, Guillemare E, et al. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature, 1996, 384(6604): 78–80.
 Calles-Escandon J, Robbins DC (1987) Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 37:1167–1172.
 Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF (2000) Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes. J Clin Endocrinol Metab 85:1081–1086.
 Hazama Y, Matsuhisa M, Ohtoshi K, et al. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pr, 2006, 71(3): 251–255.
 Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide-analysis based on the homeostasis model. Diabetes Res Clin Pr, 2003, 62(2): 87–94.
 Kudo-Fujimaki K, Hirose T, Yoshihara T et al. Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. J Diabetes Investig, 2014, 5(4):400–409.
 Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet, 2009, 41(1): 89–94.
 Lyssenko V, Nagorny CLF, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet, 2009, 41(1): 82–88.
 Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B infiuence fasting glucose levels. Nat Genet, 2009, 41(1):77–81.
 Kan MY, Zhou DZ, Zhang D, et al. Two susceptible diabetogenic variants near/in MTNR1B are associated with fasting plasma glucose in a Han Chinese cohort. Diabet Med, 2010, 27( 5): 598–602.
 Liu C, Wu Y, Li H, et al. MTNR1B rs10830963 is associated with fasting plasma glucose, HbA1C and impaired beta-cell function in Chinese Hans from Shanghai. BMC Med Genet, 2010, 11:1–7.
 Schroner Z, Javorsky M, Kozarova M, et al. Pharmacogenetics of oral antidiabetic treatment[J]. BratislLekListy, 2011, 112(8): 441–6.
 Chen M, Hu C, Jia W. Pharmacogenomics of glinides[J]. Pharmacogenomics, 2015, 16(1):45–60.
 Peschke E, Bach AG, Muhlbauer E. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res, 2006, 40( 2): 184–191.
 Stumpf I, Bazwinsky I, Peschke E. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells. J Pineal Res, 2009, 46( 2):140–147.
 Muhlbauer E, Gross E, Labucay K, et al. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol, 2009, 606(1/2/3):61–71.
 Dornhorst A． Insulinotropic meglitinide analogues. Lancet, 2001, 358( 9294): 1709–1716.
 Kirchheiner J, Meineke I, Müller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin pharmacokinet, 2004, 43(4): 267–278.
 Cheng Y, Wang G, Zhang W et al. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol, 2013, 69(3):407–413.
 Niemi M, Backman J T, Kajosaari L I, et al. Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics. Clin Pharmacol Ther, 2005, 77(6): 468–478.
 Izumi S, Nozaki Y, Maeda K et al. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos, 2015, 43(2):235–247.